Dupixent predicted to be blockbuster for Sanofi
About Richard Staines
Posts by Richard Staines:
EU regulators also backed Trelegy
Swiss company to appeal regulators’ decision.
EU regulators recommend PARP inhibitor Zejula
Novo hopes data will justify higher price compared with rival.
Cardioprotective effect occurred in patients independently of blood sugar control